KJM The Korean Journal of MedicineKorean J Med 1738-9364 2289-0769 The Korean Journal of Medicine 10.3904/kjm.2020.95.5.349 kjm-95-5-349 Erratum 제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과 The Effect of Long-term Sodium-glucose Cotransporter 2 Inhibitor Treatment on Renal Function in the Patients with Type 2 Diabetes BaekJong Ha 백종하 1 OhTae Jung 오태정 2 MoonJu-Young 문주영 3 KimTaehee 김태희 4 KoSeung Hyun 고승현 5 MoonMin Kyong 문민경 6 KimHyun Jung 김현정 7 LeeDong Won 이동원 8 HurKyu Yeon 허규연 9 The Committee of Clinical Practice Guideline, Korean Diabetes Association 대한당뇨병학회 진료지침위원회 Committee of the Cooperative Studies, Korean Society of Nephrology 대한신장학회 협연위원회 Division of Endocrinology and Metabolism, Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Gyeongsang National University College of Medicine, Changwon, Korea 경상대학교 의과대학 창원경상대학교병원 내분비대사내과 Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea 서울대학교 의과대학 분당서울대병원 내분비대사내과 Division of Nephrology, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University College of Medicine, Seoul, Korea 경희대학교 의과대학 강동경희대병원 신장내과 Division of Nephrology, Department of Internal Medicine, Busan Paik Hospital, Inje University School of Medicine, Busan, Korea 인제대학교 의과대학 부산백병원 신장내과 Division of Endocrinology and Metabolism, Department of Internal medicine, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea 가톨릭대학교 의과대학 성빈센트병원 내분비대사내과 Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea 서울대학교 의과대학 보라매병원 내분비대사내과 Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea 고려대학교 의과대학 근거중심의학연구소 Division of Nephrology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea 부산대학교 의과대학 양산부산대병원 신장내과 Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 성균관대학교 의과대학 삼성서울병원 내분비대사내과 1 10 2020 1 10 2020 95 5 349 353 Copyright © 2020 The Korean Association of Internal Medicine 2020 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Korean J Med 2020;95:236-243. https://doi.org/10.3904/kjm.2020.95.4.236

다음과 같이 본문 내 오류가 있어 수정합니다.

이득에 관한 10개의 무작위 대조 임상 연구 중 14개 논문[4,6-18]을

이득에 관한 11개의 무작위 대조임상 연구 중 12개 논문[4,6-16]을

REFERENCES

1. Jin DC. Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry. Korean J Intern Med 2015;30:17-22.

2. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA 2019;322:1294-1304.

3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.

4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357.

5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.

6. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.

7. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-384.

8. Del Prato S, Nauck M, Durán-Garcia S, et al. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data. Diabetes Obes Metab 2015;17:581-590.

9. Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract 2015;110:82-90.

10. Hollander P, Hill J, Johnson J, et al. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin. Curr Med Res Opin 2019;35:1335-1343.

11. Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME®. Circ J 2017;81:227-234.

12. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-971.

13. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther 2015;37:1773-1788.e1.

14. Merker L, Häring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med 2015;32:1555-1567.

15. Ridderstråle M, Rosenstock J, Andersen KR, Woerle HJ, Salsali A; EMPA-REG H2H-SU trial investigators. Empagliflozin compared with glimepiride in metformintreated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. Diabetes Obes Metab 2018;20:2768-2777.

16. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol 2015;14:154.

17. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-948.

18. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-136.

REFERENCES

1. Jin DC. Major changes and improvements of dialysis therapy in Korea: review of end-stage renal disease registry. Korean J Intern Med 2015;30:17-22.

2. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA 2019;322:1294-1304.

3. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128.

4. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347-357.

5. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644-657.

6. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323-334.

7. Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369-384.

8. Haering HU, Merker L, Christiansen AV, et al. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. Diabetes Res Clin Pract 2015;110:82-90.

9. Kaku K, Lee J, Mattheus M, et al. Empagliflozin and cardiovascular outcomes in Asian patients with type 2 diabetes and established cardiovascular disease - results from EMPA-REG OUTCOME®. Circ J 2017;81:227-234.

10. Kohan DE, Fioretto P, Tang W, List JF. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 2014;85:962-971.

11. Kovacs CS, Seshiah V, Merker L, et al. Empagliflozin as add-on therapy to pioglitazone with or without metformin in patients with type 2 diabetes mellitus. Clin Ther 2015;37:1773-1788.e1.

12. Merker L, Häring HU, Christiansen AV, et al. Empagliflozin as add-on to metformin in people with Type 2 diabetes. Diabet Med 2015;32:1555-1567.

13. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015;17:936-948.

14. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S; Dapagliflozin 006 Study Group. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab 2014;16:124-136.

15. Bailey CJ, Gross JL, Hennicken D, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Medicine 2013;11:43.

16. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a phase III randomized controlled trial. Cardiovasc Diabetol 2015;14:154.

Figure 3. Effect of SGLT2 inhibitors on change of (A) HbA1c, (B) body weight, (C) systolic blood pressure, and (D) diastolic blood pressure. SGLT2, sodium-glucose cotransporter 2; eGFR, estimated glomerular filtration rate; SD, standard deviation; CI, confidence interval.

Figure 3. Effect of SGLT2 inhibitors on change of (A) HbA1c, (B) body weight, (C) systolic blood pressure, and (D) diastolic blood pressure. SGLT2, sodium-glucose cotransporter 2; eGFR, estimated glomerular filtration rate; SD, standard deviation; CI, confidence interval.

Supplementary fig. 1. Study quality and risk of bias assessment. The risk of bias of each randomized controlled trial was classified as adequate (low risk of bias, green color), unclear (unclear risk of bias, yellow color), or inadequate (high risk of bias, red color) using Cochrane Risk of Bias Tool.

Supplementary fig. 1. Study quality and risk of bias assessment. The risk of bias of each randomized controlled trial was classified as adequate (low risk of bias, green color), unclear (unclear risk of bias, yellow color), or inadequate (high risk of bias, red color) using Cochrane Risk of Bias Tool.